Journal
ANTICANCER RESEARCH
Volume 37, Issue 9, Pages 5285-5291Publisher
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.11954
Keywords
Adrenal metastases; non-small cell lung cancer; oligometastases; hypofractionated stereotactic radiotherapy; metastasis; Cyberknife (R)
Categories
Ask authors/readers for more resources
Aim: The aim of this study was to evaluate the efficacy and toxicity of stereotactic body radiation therapy (SBRT) in the treatment of patients with adrenal metastases in oligometastatic non-small-cell lung cancer (NSCLC). Patients and Methods: Between November 2012 and May 2015, fifteen patients with oligometastatic non-small cell lung cancer and adrenal metastases were treated with the Cyberknife (R) system. The primary endpoint was local control. Results: The 1-year and 2-year local control rates were 60% and 46.6%, respectively. The differences in local control for patients with metachronous and synchronous metastases reached statistical significance (p= 0.00028). Two-year overall survival of 91.2% for patients with metachronous metastases was also more favourable compared to patients with synchronous adrenal metastases with 42.8%. Conclusion: Extracranial stereotactic radiotherapy with the Cyberknife (R) is a safe and non-invasive technique that extends the therapeutic spectrum in the treatment of patients with adrenal metastases in oligometastatic NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available